Skip to content
Screener

Amylyx Pharmaceuticals, Inc. AMLX Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue-
EPS-$0.46Miss by $0.02
EPS estimate-$0.44

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$59.4K
EPS estimate-$0.38

Financials

Q2 2025

Income statement

See full
Revenue-+100%
Gross profit-+100%
Operating income-$42.9M+43.8%
Net income-$41.4M+43.0%
EPS (diluted)-$0.46+57.0%

Balance sheet

See full
Cash & equivalents$58.1M-22.6%
Total debt$6.0M+89.8%
Total equity$167.9M-35.8%
Total assets$194.6M-41.4%

Cash flow

See full
Operating cash flow-$25.2M+62.1%
CapEx$17.0K-80.9%
Free cash flow-$25.3M+62.1%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$571.39M+343%
Enterprise value$519.27M+810%
P/S1,373.5×+1,373×

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-87.4%+211pp
Debt / equity0×0.0×
Current ratio8.7×+4.1×

FAQ

When did Amylyx Pharmaceuticals, Inc. report Q2 2025 earnings?
Amylyx Pharmaceuticals, Inc. (AMLX) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Amylyx Pharmaceuticals, Inc.'s Q2 2025 revenue and EPS?
Amylyx Pharmaceuticals, Inc. reported revenue of - and eps of $-0.46 for Q2 2025.
Did Amylyx Pharmaceuticals, Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.44 by $0.02.
How did Amylyx Pharmaceuticals, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $1.0M a year earlier and eps grew 37.0% from $-0.73.
Where can I find Amylyx Pharmaceuticals, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-104546) and the 10-Q periodic report (0001193125-25-174948) directly on SEC EDGAR. The filing index links above go to sec.gov.